Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device Business Strategies

Johnson & Johnson CEO Gorsky Reaffirms Diversified Strategy

This article was originally published in The Gray Sheet

  • News

Executive Summary

Faced with spin-off models from other diversified health care firms, including Abbott and Pfizer, Gorsky defended J&J’s broader-based approach as a better long-term strategy.

You may also be interested in...



People In Brief

Gorsky assumes chairmanship at J&J. John Yonkin named CEO at Immunetics. More news on people in the device and diagnostics industries.

Biomet Cites Q4 Sales Boost From JuggerKnot Sports Med Implants

The company’s sports, extremities and trauma products generated 14% growth last quarter with the help of its JuggerKnot Soft Anchor sports medicine products.

J&J Eyes Restructured Device Biz As New CEO Gorsky Steps In

Big changes are underway at J&J. In April, Alex Gorsky will become the company’s new CEO. And the firm plans a restructuring of its device business upon completion of its $20 billion-plus Synthes acquisition in the first half of the year.

Table

View full table

Topics

Related Companies

Tags:
Medical Device Business Strategies
Latest Headlines

Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel

Philips Portfolio Includes ‘No Single Product That Does Not Use A Type Of AI,’ Says CEO And AI Thought Leader Roy Jakobs

More Heartmate Troubles For Abbott. Latest Recall Includes 14 Deaths

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

See All
UsernamePublicRestriction

Register

MT031409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By